Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory

 

 

 
AMT and St. Jude Partner to Develop Hemophilia B Gene Therapy
 

In July, Amsterdam Molecular Therapeutics (AMT), a Netherlands-based company specializing in human gene therapy, announced its collaboration with St. Jude Children’s Research Hospital in Memphis, TN, to develop a gene therapy for hemophilia B patients. The treatment will use AMT’s proprietary adeno-associated virus (AAV) vectors, which are employed as vehicles for delivering the targeted therapeutic genes.

The drug development research will be conducted at St. Jude’s, while AMT will hold exclusive commercial rights to the final product.

AMT’s unique gene therapy platform appears to circumvent some of the obstacles that have prevented gene therapy success in the past. The goal is to cure patients of hemophilia B with a single administration of the product. Many patients currently self-infuse the clotting factor up to three times weekly.

“The importance of this collaboration with renowned St. Jude Children’s Research Hospital stretches beyond its scientific and business aspects. This collaboration will bring to these patients the hope that a real cure is on the horizon,” said Ronald Lorijn, CEO of AMT.

Source: AMT news release dated July 15, 2008